EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR Breaking the silence: when cancer steals your voice December 2, 2022 Coping With War and Cancer: How to Take Care of Your... March 11, 2022 Workout Wednesday – Leg Stretches Part 2 July 15, 2020 Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... April 15, 2025 Load more HOT NEWS Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab Signal of Increased Risk of Major Cardiovascular Events and Cancer with... FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC...
